Date:   2/21/2014 1:50:15 PM ( 10 y ago)
Hits:   5,026
URL:   https://www.curezone.org/forums/fm.asp?i=2152418

0 of 0 (0%) readers agree with this message.  Hide votes     What is this?

No studies or scientific evidence?  An erroneous meme perpetuated once again!

From PubMed:  70+ recent studies done by researchers world-wide and published in well know journals  just focusing on vaccine safety with flu vaccinations:

Greene SK, Kulldorff M, Lewis EM et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am. J. Epidemiol. 171(2), 177–188(2010).

Lee GM, Greene SK, Weintraub ES et al.; Vaccine Safety Datalink Project. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. Am. J. Prev. Med. 41(2), 121–128(2011).

Wright PF, Sell SH, Thompson J, Karzon DT. Clinical reactions and serologic response following inactivated monovalent influenza type B vaccine in young children and infants. J. Pediatr. 88(1), 31–35(1976).

Vasil'eva RI, Merkur'eva LA, Iatsenko VG, Vasil'eva AM, Shvager MM. Characteristics of the clinical and immunologic safety of inactivated influenza vaccines in children undergoing multiple immunizations. Zh. Mikrobiol. Epidemiol. Immunobiol. 11, 65–69(1988).

Beutner KR, Chow T, Rubi E, Strussenberg J, Clement J, Ogra PL. Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. J. Infect. Dis. 140(6), 844–850(1979).

Barry DW, Mayner RE, Hochstein HD et al. Comparative trial of influenza vaccines. II. Adverse reactions in children and adults. Am. J. Epidemiol. 104(1), 47–59(1976).

France EK, Glanz JM, Xu S et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch. Pediatr. Adolesc. Med. 158(11), 1031–1036(2004).

Glanz JM, Newcomer SR, Hambidge SJ et al. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Arch. Pediatr. Adolesc. Med. 165(8), 749–755(2011).

Hambidge SJ, Glanz JM, France EK et al.; Vaccine Safety Datalink Team. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA 296(16), 1990–1997(2006).
(Provides information on the safety of inactivated influenza vaccine in a large population of children 6–23 months of age.)

El'shina GA, Gorbunov MA, Bektimirov TA et al. The evaluation of the reactogenicity, harmlessness and prophylactic efficacy of Grippol trivalent polymer-subunit influenza vaccine administered to schoolchildren. Zh. Mikrobiol. Epidemiol. Immunobiol. (2), 50–54(2000).

Baxter R, Jeanfreau R, Block SL et al. A Phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. Pediatr. Infect. Dis. J. 29(10), 924–930(2010).

Bohlke K, Davis RL, Marcy SM et al.; Vaccine Safety Datalink Team. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 112(4), 815–820(2003).

Kelso JM. Administration of influenza vaccines to patients with egg allergy. J. Allergy Clin. Immunol. 125(4), 800–802(2010).

Kelso JM, Li JT, Nicklas RA et al.; Joint Task Force on Practice Parameters; Joint Task Forcce on Practice Parameters for Allergy & Immunology. Adverse reactions to vaccines. Ann. Allergy Asthma Immunol. 103(4 Suppl. 2), S1–S14(2009).

Kelso JM. Update on vaccination guidelines for allergic children. Expert Rev. Vaccines 8(11), 1541–1546(2009).

Wood RA, Berger M, Dreskin SC et al.; Hypersensitivity Working Group of the Clinical Immunization Safety Assessment (CISA) Network. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics 122(3), e771–e777(2008).

Armstrong PK, Dowse GK, Effler PV et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open 1(1), e000016(2011).
(Provides results of epidemiologic investigations of febrile seizure following administration of inactivated influenza vaccine in Western Australia.)

Rosenberg M, Sparks R, McMahon A, Iskander J, Campbell JD, Edwards KM. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6–23 months of age. Vaccine 27(32), 4278–4283(2009).

McMahon AW, Iskander J, Haber P et al. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990–2003. Pediatrics 115(2), 453–460(2005).

Wood N, Sheppeard V, Cashman P et al. Influenza vaccine safety in children less than 5 years old: the 2010 and 2011 experience in Australia. Pediatr. Infect. Dis. J. 31(2), 199–202(2012).

Blyth CC, Currie AJ, Wiertsema SP et al. Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms. Vaccine 29(32), 5107–5113(2011).

Varricchio F, Iskander J, Destefano F et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr. Infect. Dis. J. 23(4), 287–294(2004).

Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM; VSD Rapid Cycle Analysis Influenza Working Group. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010–2011. Vaccine 30(11), 2024–2031(2012).

Nohynek H, Jokinen J, Partinen M et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 7(3), e33536(2012).

Partinen M, Saarenpää-Heikkilä O, Ilveskoski I et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 7(3), e33723(2012).

Belshe RB, Ambrose CS, Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2–7 years of age. Vaccine 26(Suppl. 4), D10–D16(2008).

Bergen R, Black S, Shinefield H et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr. Infect. Dis. J. 23(2), 138–144(2004).

Gaglani MJ, Piedra PA, Riggs M, Herschler G, Fewlass C, Glezen WP. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr. Infect. Dis. J. 27(5), 444–452(2008).

King JC Jr, Lagos R, Bernstein DI et al. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J. Infect. Dis. 177(5), 1394–1397(1998).

Nolan T, Lee MS, Cordova JM et al. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities. Vaccine 21(11–12), 1224–1231(2003).

Piedra PA, Gaglani MJ, Riggs M et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 116(3), e397–e407(2005).

Piedra PA, Yan L, Kotloff K et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 110(4), 662–672(2002).

Redding G, Walker RE, Hessel C et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr. Infect. Dis. J. 21(1), 44–48(2002).

Zangwill KM, Droge J, Mendelman P et al. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatr. Infect. Dis. J. 20(8), 740–746(2001).

Desheva IUA, Danini GV, Grigor'eva EP et al. The investigation of the safety, genetic stability and immunogenicity of live influenza vaccine for adults in vaccination of 3–6 years old children. Vopr. Virusol. 47(4), 21–24(2002).

Gruber WC, Belshe RB, King JC et al. Evaluation of live attenuated influenza vaccines in children 6–18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group. J. Infect. Dis. 173(6), 1313–1319(1996).

Nolan T, Bernstein DI, Block SL et al.; LAIV Study Group. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics 121(3), 508–516(2008).

Baxter R, Toback SL, Sifakis F et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18–49 years of age. Vaccine 30(20), 3053–3060(2012).

Govaert TM, Dinant GJ, Aretz K, Masurel N, Sprenger MJ, Knottnerus JA. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ 307(6910), 988–990(1993).
(Results of a randomized controlled trial to investigate the frequency and type of adverse events following administration of influenza vaccine among the elderly.)

Margolis KL, Nichol KL, Poland GA, Pluhar RE. Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebo-controlled trial. JAMA 264(9), 1139–1141(1990).

Keitel WA, Atmar RL, Cate TR et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch. Intern. Med. 166(10), 1121–1127(2006).

Schwarz TF, Flamaing J, Rümke HC et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged =65 years. Vaccine 29(32), 5195–5202(2011).

Weston WM, Chandrashekar V, Friedland LR, Howe B. Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults. Hum. Vaccin. 5(12), 858–866(2009).

Kerzner B, Murray AV, Cheng E et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J. Am. Geriatr. Soc. 55(10), 1499–1507(2007).

McNeil SA, Noya F, Dionne M et al. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. Vaccine 25(17), 3464–3474(2007).

Sejvar JJ, Kohl KS, Gidudu J et al.; Brighton Collaboration GBS Working Group. Guillain–Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29(3), 599–612(2011).

Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ et al. Guillain–Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am. J. Epidemiol. 110(2), 105–123(1979).
(Results of epidemiologic investigations of Guillain–Barré syndrome following administration of a swine influenza virus vaccine during a national immunization program.)

Hurwitz ES, Schonberger LB, Nelson DB, Holman RC. Guillain–Barré syndrome and the 1978–1979 influenza vaccine. N. Engl. J. Med. 304(26), 1557–1561(1981).

Kaplan JE, Katona P, Hurwitz ES, Schonberger LB. Guillain–Barré syndrome in the United States, 1979–1980 and 1980–1981. Lack of an association with influenza vaccination. JAMA 248(6), 698–700(1982).

Burwen DR, Ball R, Bryan WW et al. Evaluation of Guillain–Barré Syndrome among recipients of influenza vaccine in 2000 and 2001. Am. J. Prev. Med. 39(4), 296–304(2010).

Hughes RA, Charlton J, Latinovic R, Gulliford MC. No association between immunization and Guillain–Barré syndrome in the United Kingdom, 1992 to 2000. Arch. Intern. Med. 166(12), 1301–1304(2006).

Roscelli JD, Bass JW, Pang L. Guillain–Barré syndrome and influenza vaccination in the US Army, 1980–1988. Am. J. Epidemiol. 133(9), 952–955(1991).

Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain–Barré syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am. J. Epidemiol. 169(3), 382–388(2009).

Lasky T, Terracciano GJ, Magder L et al. The Guillain–Barré syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N. Engl. J. Med. 339(25), 1797–1802(1998).

Juurlink DN, Stukel TA, Kwong J et al. Guillain–Barré syndrome after influenza vaccination in adults: a population-based study. Arch. Intern. Med. 166(20), 2217–2221(2006).

Baxter R, Lewis N, Bakshi N, Vellozzi C, Klein NP; CISA Network. Recurrent Guillain–Barré syndrome following vaccination. Clin. Infect. Dis. 54(6), 800–804(2012).

Moro PL, Broder K, Zheteyeva Y et al. Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System. Am. J. Obstet. Gynecol. 205(5), 473.e1–473.e9(2011).

Salmon DA, Akhtar A, Mergler MJ et al.; H1N1 Working Group of Federal Immunization Safety Task Force. Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program. Pediatrics 127(Suppl. 1), S78–S86(2011).

Williams SE, Pahud BA, Vellozzi C et al. Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination. Vaccine 29(46), 8302–8308(2011).

Andrews N, Stowe J, Al-Shahi Salman R, Miller E. Guillain–Barré syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series. Vaccine 29(45), 7878–7882(2011).

Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturkenboom M; VAESCO-GBS Case-Control Study Group. Guillain–Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ 343, d3908(2011).

Preliminary results: surveillance for Guillain–Barré syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine – United States, 2009–2010. MMWR Morb. Mortal Wkly. Rep. 59(21), 657–661(2010).

Greene SK, Rett M, Weintraub ES et al. Risk of confirmed Guillain–Barré syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009–2010. Am. J. Epidemiol. 175(11), 1100–1109(2012).

Wise ME, Viray M, Sejvar JJ et al. Guillain–Barré syndrome during the 2009–2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans. Am. J. Epidemiol. 175(11), 1110–1119(2012).

Jackson LA, Holmes SJ, Mendelman PM, Huggins L, Cho I, Rhorer J. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 17(15–16), 1905–1909(1999).

Halperin SA, Nestruck AC, Eastwood BJ. Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture. Vaccine 16(13), 1331–1335(1998).

Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine 27(5), 786–791(2009).

Palache AM, Brands R, van Scharrenburg GJ. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J. Infect. Dis. 176(Suppl. 1), S20–S23(1997).

Palache AM, Scheepers HS, de Regt V et al. Safety, reactogenicity and immunogenicity of Madin Darby Canine Kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies. Dev. Biol. Stand. 98, 115–25; discussion 133(1999).

Halperin SA, Smith B, Mabrouk T et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 20(7–8), 1240–1247(2002).

Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J. Infect. Dis. 200(6), 849–857(2009).

Keitel W, Groth N, Lattanzi M et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a Phase 1/2 clinical trial. Vaccine 28(3), 840–848(2010).

Szymczakiewicz-Multanowska A, Groth N, Bugarini R et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J. Infect. Dis. 200(6), 841–848(2009).

López-Macías C, Ferat-Osorio E, Tenorio-Calvo A et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 29(44), 7826–7834(2011).

Lewis DJ, Huo Z, Barnett S et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 4(9), e6999(2009).

Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350(9), 896–903(2004).

Nicholson KG, Abrams KR, Batham S et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect. Dis. 11(2), 91–101(2011).

Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age. Vaccine 29(12), 2272–2278(2011).

<< Return to the standard message view

fetched in 0.02 sec, referred by http://www.curezone.org/forums/fmp.asp?i=2152418